|
Treatment-naïve patients
|
|
N
|
678
|
111
|
66
|
|
Response rate†, n (%; 95% CI)
|
441 (65.04; 61.32–68.63)
|
60 (54.05; 44.33–63.55)
|
51 (77.27; 65.30–86.68)
|
|
No effect, n (%)
|
237 (34.95)
|
51 (45.94)
|
15 (22.72)
|
|
Patients switched from EPO
|
|
N
|
160
|
399
|
20
|
|
Response rate‡, n (%; 95% CI)
|
109 (68.12; 60.30–75.25)
|
279 (69.92; 65.16–74.38)
|
12 (60.00; 36.05–80.88)
|
|
No effect, n (%)
|
51 (31.87)
|
120 (30.07)
|
8 (40.00)
|
|
Patients switched from DA
|
|
N
|
265
|
383
|
146
|
|
Response rate†, n (%; 95% CI)
|
162 (61.13; 54.97–67.03)
|
256 (66.84; 61.87–71.53)
|
99 (67.80; 59.58–75.29)
|
|
No effect, n (%)
|
103 (38.86)
|
127 (33.15)
|
47 (32.19)
|
